{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:36:30Z","timestamp":1792798590183,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA197579"],"award-info":[{"award-number":["R35CA197579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UH3CA241685"],"award-info":[{"award-number":["UH3CA241685"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cure Brain Cancer Foundation Innovation Grant","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/02db9yt31","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Australian Brain Cancer Mission Innovative Clinical Trials Scheme","award":["MRF9500003"],"award-info":[{"award-number":["MRF9500003"]}]},{"name":"Medical Research Future Fund (MRFF) Lifting Clinical Trials and Registries Capacity scheme","award":["MRF1152501"],"award-info":[{"award-number":["MRF1152501"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,7,8]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Glioblastoma is the most common aggressive primary central nervous system cancer in adults characterised by uniformly poor survival. Despite maximal safe resection and postoperative radiotherapy with concurrent and adjuvant temozolomide-based chemotherapy, tumours inevitably recur. Imaging with O-(2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]-fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) has the potential to impact adjuvant radiotherapy (RT) planning, distinguish between treatment-induced pseudoprogression versus tumour progression as well as prognostication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The FET-PET in Glioblastoma (FIG) study is a prospective, multicentre, non-randomised, phase II study across 10 Australian sites and will enrol up to 210 adults aged \u226518 years with newly diagnosed glioblastoma. FET-PET will be performed at up to three time points: (1) following initial surgery and prior to commencement of chemoradiation (FET-PET1); (2) 4 weeks following concurrent chemoradiation (FET-PET2); and (3) within 14 days of suspected clinical and\/or radiological progression on MRI (performed at the time of clinical suspicion of tumour recurrence) (FET-PET3). The co-primary outcomes are: (1) to investigate how FET-PET versus standard MRI impacts RT volume delineation and (2) to determine the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression. The secondary outcomes are: (1) to investigate the relationships between FET-PET parameters (including dynamic uptake, tumour to background ratio, metabolic tumour volume) and progression-free survival and overall survival; (2) to assess the change in blood and tissue biomarkers determined by serum assay when comparing FET-PET data acquired prior to chemoradiation with other prognostic markers, looking at the relationships of FET-PET versus MRI-determined site\/s of progressive disease post chemotherapy treatment with MRI and FET-PET imaging; and (3) to estimate the health economic impact of incorporating FET-PET into glioblastoma management and in the assessment of post-treatment pseudoprogression or recurrence\/true progression. Exploratory outcomes include the correlation of multimodal imaging, blood and tumour biomarker analyses with patterns of failure and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol V.2.0 dated 20 November 2020 has been approved by a lead Human Research Ethics Committee (Austin Health, Victoria). Other clinical sites will provide oversight through local governance processes, including obtaining informed consent from suitable participants. The study will be conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. Results of the FIG study (TROG 18.06) will be disseminated via relevant scientific and consumer forums and peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ANZCTR ACTRN12619001735145<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-071327","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T12:34:19Z","timestamp":1691152459000},"page":"e071327","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["[\n                    <sup>18<\/sup>\n                    F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET\/CT trial"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-2513","authenticated-orcid":false,"given":"Eng-Siew","family":"Koh","sequence":"first","affiliation":[{"name":"Radiation Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia"},{"name":"South West Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7319-8546","authenticated-orcid":false,"given":"Hui K","family":"Gan","sequence":"additional","affiliation":[{"name":"Austin Health, Department of Medical Oncology, Melbourne, Victoria, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia"},{"name":"Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia"},{"name":"School of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5232-4491","authenticated-orcid":false,"given":"Clare","family":"Senko","sequence":"additional","affiliation":[{"name":"School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia"},{"name":"Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia"},{"name":"Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1351","authenticated-orcid":false,"given":"Roslyn J","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"},{"name":"Medical School, The University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-0719","authenticated-orcid":false,"given":"Martin","family":"Ebert","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia"},{"name":"School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-456X","authenticated-orcid":false,"given":"Sze Ting","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia"},{"name":"Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia"},{"name":"School of Medicine, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1261-7775","authenticated-orcid":false,"given":"Eddie","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Department of Radiology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Radiology, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-9849","authenticated-orcid":false,"given":"Mustafa","family":"Khasraw","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-9526","authenticated-orcid":false,"given":"Anna K","family":"Nowak","sequence":"additional","affiliation":[{"name":"Medical School, The University of Western Australia, Crawley, Western Australia, Australia"},{"name":"Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-7957","authenticated-orcid":false,"given":"Dale L","family":"Bailey","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Health, University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-4801","authenticated-orcid":false,"given":"Bradford A","family":"Moffat","sequence":"additional","affiliation":[{"name":"Melbourne Brain Centre Imaging Unit, Department of Radiology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-9654","authenticated-orcid":false,"given":"Greg","family":"Fitt","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Radiology, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-0824","authenticated-orcid":false,"given":"Rodney J","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Centre for Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2180-3844","authenticated-orcid":false,"given":"Robert","family":"Coffey","sequence":"additional","affiliation":[{"name":"Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-0436","authenticated-orcid":false,"given":"Roel","family":"Verhaak","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-9981","authenticated-orcid":false,"given":"Kyle M","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5128","authenticated-orcid":false,"given":"Elizabeth H","family":"Barnes","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-8774","authenticated-orcid":false,"given":"Richard","family":"De Abreu Lourenco","sequence":"additional","affiliation":[{"name":"Centre for Health Economics Research and Evaluation, University of Technology Sydney, Broadway, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-6764","authenticated-orcid":false,"given":"Mark","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8562-364X","authenticated-orcid":false,"given":"Lucas","family":"Adda","sequence":"additional","affiliation":[{"name":"The Cooperative Trials Group for Neuro-Oncology (COGNO) Consumer Advisor Panel, National Health and Medical Research Council (NHMRC) Clinical Trials Centre (CTC), University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-0965","authenticated-orcid":false,"given":"Farshad","family":"Foroudi","sequence":"additional","affiliation":[{"name":"School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia"},{"name":"Department of Radiation Oncology, Austin Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-3015","authenticated-orcid":false,"given":"Arian","family":"Lasocki","sequence":"additional","affiliation":[{"name":"Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-9289","authenticated-orcid":false,"given":"Alisha","family":"Moore","sequence":"additional","affiliation":[{"name":"Trans Tasman Radiation Oncology Group (TROG), Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0950","authenticated-orcid":false,"given":"Paul A","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Royal Brisbane and Women\u2019s Hospital, Brisbane, Queensland, Australia"},{"name":"Faculty of Medicine, The University of Queensland, Saint Lucia, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2504-0474","authenticated-orcid":false,"given":"Paul","family":"Roach","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia"},{"name":"The University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2363-8333","authenticated-orcid":false,"given":"Michael","family":"Back","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia"},{"name":"Faculty of Medicine & Health, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4454-7617","authenticated-orcid":false,"given":"Robyn","family":"Leonard","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6656-295X","authenticated-orcid":false,"given":"Andrew M","family":"Scott","sequence":"additional","affiliation":[{"name":"School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia"},{"name":"Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia"},{"name":"School of Medicine, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"2025121400060339000_13.8.e071327.1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab200"},{"key":"2025121400060339000_13.8.e071327.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"2025121400060339000_13.8.e071327.3","doi-asserted-by":"crossref","unstructured":"Perry JR , Laperriere N , Mason WP . Radiation plus Temozolomide in patients with glioblastoma. N Engl J Med 2017;376. doi:10.1056\/NEJMc1704726","DOI":"10.1056\/NEJMc1704726"},{"key":"2025121400060339000_13.8.e071327.4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now058"},{"key":"2025121400060339000_13.8.e071327.5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab013"},{"key":"2025121400060339000_13.8.e071327.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.01.006"},{"key":"2025121400060339000_13.8.e071327.7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijrobp.2010.05.054","article-title":"Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison","volume":"81","author":"Pinkawa","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121400060339000_13.8.e071327.8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00259-016-3494-2","article-title":"The Prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma","volume":"44","author":"Poulsen","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025121400060339000_13.8.e071327.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.096859"},{"key":"2025121400060339000_13.8.e071327.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4207-9"},{"key":"2025121400060339000_13.8.e071327.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.12.003"},{"key":"2025121400060339000_13.8.e071327.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.03.001"},{"key":"2025121400060339000_13.8.e071327.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.06.043"},{"key":"2025121400060339000_13.8.e071327.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.08.043"},{"key":"2025121400060339000_13.8.e071327.15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s12094-017-1816-x","article-title":"Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, Pseudoprogression, Pseudoresponse and Radionecrosis","volume":"20","author":"Delgado-L\u00f3pez","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"2025121400060339000_13.8.e071327.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2959-4"},{"key":"2025121400060339000_13.8.e071327.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1334"},{"key":"2025121400060339000_13.8.e071327.18","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.3390\/cancers12123835","article-title":"FET PET Radiomics for differentiating Pseudoprogression from early tumor progression in glioma patients post-Chemoradiation","volume":"12","author":"Lohmann","year":"2020","journal-title":"Cancers"},{"key":"2025121400060339000_13.8.e071327.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.4969"},{"key":"2025121400060339000_13.8.e071327.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70125-6"},{"key":"2025121400060339000_13.8.e071327.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"2025121400060339000_13.8.e071327.22","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa141"},{"key":"2025121400060339000_13.8.e071327.23","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0507-6"},{"key":"2025121400060339000_13.8.e071327.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234757"},{"key":"2025121400060339000_13.8.e071327.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2018.04.003"},{"key":"2025121400060339000_13.8.e071327.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.03.179"},{"key":"2025121400060339000_13.8.e071327.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05114-0"},{"key":"2025121400060339000_13.8.e071327.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4180-3"},{"key":"2025121400060339000_13.8.e071327.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263790"},{"key":"2025121400060339000_13.8.e071327.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2009.05.009"},{"key":"2025121400060339000_13.8.e071327.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.103325"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-071327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:06:09Z","timestamp":1765699569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-071327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,4]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjopen-2022-071327"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-071327","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}